TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04685538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 3%
Description: Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine 0.5%
Description: Administration: three IMP drops instillation as follow:~* 1st Drop instillation, then wait for 5 minutes~* Eye Disinfection, then wait for 2 minutes~* 2nd Drop instillation, then wait for 1 minute~* 3rdDrop instillation, then wait for 1 minute~* Start of Surgery.
Study: NCT03142087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: exercise
Study: NCT05453604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colli-Pee UAS devices
Description: Colli-Pee UAS device variants will be evaluated during this study
Study: NCT03040102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospice Video Educational Tool
Description: it's a 6 minute video regarding hospice care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care practice is used
Study: NCT01731990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab (ACZ885)
Description: Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of Canakinumab
Study: NCT03463382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine (Block Drug)
Description: 0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
Study: NCT04051112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: 10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
Study: NCT01784978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg pd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg pd
Study: NCT04748523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
Study: NCT02920450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg
Study: NCT03256331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEL-X-HG
Description: This study will be carried out in 2 parts:~1. A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~2. A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 5 study cohorts and one modified dose will be as follows:~* Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~* Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~* Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~* Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid) Modified dose level Cohort 5: Dose level 5 - 1.5 g/day (0.75g bid) This re-escalation is allowed only when dose de-escalates from Dose level 3 to Dose level 2, and 1 DLT in 6 evaluable subjects of Dose level 2.
Study: NCT03330821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01293539

Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan hydrochloride
Description: Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (\>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle.
Study: NCT04457336

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tildacerfont/Placebo
Description: Tablet, administered daily
Study: NCT02920450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg
Study: NCT03286010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women@Heart Program
Description: The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
Study: NCT05302830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snackability app
Description: This app allows user to search for a snack (scan barcode or type snack name), add a portion size consumed based on a portion size guide, and then provide a snack score and breakdown scores with a specific feedback message about the score.25 A score ranging from 0-10 points was designed taking into account the first ingredient, the nutrient standard by portion size, and the processing of foods (score ranging from -1 to 1 was subtracted or added depend on processed food classification). The final score ranged from -1 to 11 points. The higher the score, the more compliant it is to the guideline; therefore, the healthier the snack is. The app also provides gamification features as self-motivation (level up and achievement gained) and reporting features as goal-setting and self-monitoring (average daily score and consumed snack history).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group received a 1-page with information on what is a healthy snack from the USDA: https://www.fns.usda.gov/cn/tools-schools-focusing-smart-snacks. They were given access to the app after the 12-week study period.
Study: NCT02920450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
Study: NCT01921452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quantitative POC TSH Kit
Description: A drop (approximately 30 microliter \[mcL\]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
Study: NCT04885153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Patients were given simvastatin 10 mg and fenofibrate 200 mg daily for three months and were evaluated monthly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were given simvastatin 10 mg and placebo (lactic acid) 200 mg daily for three months and were evaluated monthly.
Study: NCT02992418

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 milliliter (mL), Subcutaneous at Month 1, 7 and Month 13, respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed
Description: 0.5 mL, intramuscularly (IM) at Month 1.
Study: NCT03169868

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sano Patient Medication Profile
Description: The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
Study: NCT03200431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New adhesive strip
Description: This is a newly developed strip.
Study: NCT00588237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel,Cisplatin, Bevacizumab
Description: IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
Study: NCT02792309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MotherWise Program
Description: Healthy Marriage or Relationship Education services for pregnant women.
Study: NCT02096952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate extended-release liquid formulation
Study: NCT03275246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-PSI Knee System
Description: Patients are operated with X-PSI Knee System guides
Study: NCT03999099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant 20 mg
Description: Suvorexant at a high dose (20 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant 10 mg
Description: Suvorexant at a low dose (10 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT00635349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac
Description: Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
Study: NCT01784978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg pd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 10 mg pd
Study: NCT00009698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SQ and IV
Study: NCT01506713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel Tablets 75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel Tablets 75 mg
Study: NCT01165437

Intervention type: DEVICE
Intervention: Blood Pressure Measurement
Description: Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
Study: NCT03644212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
Study: NCT00590720

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI528 50 mg
Description: MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo administered as a subcutaneous injection twice weekly for 4 weeks
Study: NCT00224042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate complex in sucrose
Description: Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: ferrous sulfate 325 mg three times daily for 6 weeks
Study: NCT04717791

Intervention type: DEVICE
Group type: OTHER
Intervention: Vivaer® ARC Stylus
Description: The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions
Study: NCT00766311

Intervention type: OTHER
Group type: OTHER
Intervention: Gross Motor Function
Description: The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.

Intervention type: OTHER
Group type: OTHER
Intervention: Knee extension strength
Description: Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken.

Intervention type: OTHER
Group type: OTHER
Intervention: Hand grip strength
Description: Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Flexibility
Description: Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.

Intervention type: OTHER
Group type: OTHER
Intervention: Ankle range of motion
Description: Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic capacity
Description: Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02

Intervention type: OTHER
Group type: OTHER
Intervention: Body composition and vital signs
Description: Height, body mass index, waist circumference, and blood pressure will be measured.
Study: NCT02069717

Intervention type: OTHER
Intervention: Not applicable-observational study
Study: NCT05492838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implantation with the Socket Shield Technique
Description: Immediate implant surgery applied with the Socket Shield Technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate implantation with the Socket Shield Technique
Description: Immediate implant surgery applied with the Socket Shield Technique
Study: NCT02198066

Intervention type: OTHER
Group type: OTHER
Intervention: Dry Sterile Dressing
Description: Described in Arm Description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metallic Silver Dressing
Description: Described in Arm Description.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ionic Silver Dressing
Description: Described in Arm Description.
Study: NCT01748669

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic oil
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garlic oil
Description: Oral administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Garlic oil
Description: Oral administration
Study: NCT04277416

Intervention type: DEVICE
Intervention: Total Hip Arthroplasty
Description: To evaluate Implant survival based on removal or intended removal of any component of the Entrada™ Hip System at five years of follow-up.
Study: NCT02430012

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality improvement strategies
Description: Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
Study: NCT02164500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Study: NCT01921452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Qualitative POC TSH Kit
Description: A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Third generation TSH Kit
Description: One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
Study: NCT02522078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dry misoprostol
Description: 400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: wet misoprostol
Description: 400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation